Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1992 2
1993 10
1994 5
1995 4
2005 1
2006 1
2007 2
2008 1
2009 2
2012 1
2013 1
2014 2
2017 1
2020 2
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for L. pienta
Your search for L. Pienti retrieved no results
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Phillips R, et al. JAMA Oncol. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147. JAMA Oncol. 2020. PMID: 32215577 Free PMC article. Clinical Trial.
Classification of current anticancer immunotherapies.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
Risk factors for prostate cancer.
Pienta KJ, Esper PS. Pienta KJ, et al. Ann Intern Med. 1993 May 15;118(10):793-803. doi: 10.7326/0003-4819-118-10-199305150-00007. Ann Intern Med. 1993. PMID: 8470854 Review.
Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/galectin-3 inhibitor lactulose-L-leucine.
Glinskii OV, Sud S, Mossine VV, Mawhinney TP, Anthony DC, Glinsky GV, Pienta KJ, Glinsky VV. Glinskii OV, et al. Neoplasia. 2012 Jan;14(1):65-73. doi: 10.1593/neo.111544. Neoplasia. 2012. PMID: 22355275 Free PMC article.
This study investigated the ability of a synthetic small-molecular-weight nontoxic carbohydrate-based TF-Ag mimic lactulose-L-leucine (Lac-L-Leu) to inhibit these processes in vitro and, ultimately, prostate cancer bone metastasis in vivo. ...We report that daily in …
This study investigated the ability of a synthetic small-molecular-weight nontoxic carbohydrate-based TF-Ag mimic lactulose-L-leucine …
A large, curated, open-source stroke neuroimaging dataset to improve lesion segmentation algorithms.
Liew SL, Lo BP, Donnelly MR, Zavaliangos-Petropulu A, Jeong JN, Barisano G, Hutton A, Simon JP, Juliano JM, Suri A, Wang Z, Abdullah A, Kim J, Ard T, Banaj N, Borich MR, Boyd LA, Brodtmann A, Buetefisch CM, Cao L, Cassidy JM, Ciullo V, Conforto AB, Cramer SC, Dacosta-Aguayo R, de la Rosa E, Domin M, Dula AN, Feng W, Franco AR, Geranmayeh F, Gramfort A, Gregory CM, Hanlon CA, Hordacre BG, Kautz SA, Khlif MS, Kim H, Kirschke JS, Liu J, Lotze M, MacIntosh BJ, Mataró M, Mohamed FB, Nordvik JE, Park G, Pienta A, Piras F, Redman SM, Revill KP, Reyes M, Robertson AD, Seo NJ, Soekadar SR, Spalletta G, Sweet A, Telenczuk M, Thielman G, Westlye LT, Winstein CJ, Wittenberg GF, Wong KA, Yu C. Liew SL, et al. Sci Data. 2022 Jun 16;9(1):320. doi: 10.1038/s41597-022-01401-7. Sci Data. 2022. PMID: 35710678 Free PMC article.
Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer.
Trabzonlu L, Pienta KJ, Trock BJ, De Marzo AM, Amend SR. Trabzonlu L, et al. Prostate. 2023 Feb;83(3):277-285. doi: 10.1002/pros.24459. Epub 2022 Nov 13. Prostate. 2023. PMID: 36372998 Free PMC article.
MATERIALS AND METHODS: Men with National Comprehensive Cancer Network intermediate- or high-risk PCa who underwent radical prostatectomy l from 2007 to 2015 and who did not receive neoadjuvant treatment were included. ...
MATERIALS AND METHODS: Men with National Comprehensive Cancer Network intermediate- or high-risk PCa who underwent radical prostatectomy …
41 results